These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 189741)
21. Demonstration of Epstein-Barr virus-specific DNA polymerase in chemically induced Raji cells and its antibody in serum from patients with nasopharyngeal carcinoma. Tan RS; Li JS; Grill SP; Nutter LM; Cheng YC Cancer Res; 1986 Oct; 46(10):5024-8. PubMed ID: 3019519 [TBL] [Abstract][Full Text] [Related]
22. Factors affecting serum IgA antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma. Ho HC; Ng MH; Kwan HC Br J Cancer; 1978 Mar; 37(3):356-62. PubMed ID: 205232 [TBL] [Abstract][Full Text] [Related]
24. Detection of IgG and IgA antibodies to Epstein-Barr virus membrane antigen in sera from patients with nasopharyngeal carcinoma and from normal individuals. Zhu XX; Zeng Y; Wolf H Int J Cancer; 1986 May; 37(5):689-91. PubMed ID: 3009331 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma. Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579 [TBL] [Abstract][Full Text] [Related]
26. Antibody against Epstein-Barr virus DNA polymerase activity in sera of patients with nasopharyngeal carcinoma. Liu MY; Chou WH; Nutter L; Hsu MM; Chen JY; Yang CS J Med Virol; 1989 Jun; 28(2):101-5. PubMed ID: 2544674 [TBL] [Abstract][Full Text] [Related]
27. [Immunoglobulin A serum antibodies against the capsid antigen of Epstein-Barr virus in the differential diagnosis and follow-up of nasopharyngeal cancer]. Pavelka R; Popow-Kraupp T; Radaszkiewicz T Wien Klin Wochenschr; 1985 Jul; 97(14):588-95. PubMed ID: 2996246 [TBL] [Abstract][Full Text] [Related]
28. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma. Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156 [TBL] [Abstract][Full Text] [Related]
29. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545 [TBL] [Abstract][Full Text] [Related]
30. Nasopharyngeal carcinoma in American Children: Epstein-Barr virus-specific antibody titers and prognosis. Naegele RF; Champion J; Murphy S; Henle G; Henle W Int J Cancer; 1982 Feb; 29(2):209-12. PubMed ID: 6174465 [TBL] [Abstract][Full Text] [Related]
31. Clinical aspects and natural history of nasopharyngeal carcinoma in Western Europe. Cachin Y; Schwaab G; Sancho-Garnier H; Marandas P IARC Sci Publ (1971); 1978; (20):131-45. PubMed ID: 215512 [No Abstract] [Full Text] [Related]
32. Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma. Wong MM; Lye MS; Cheng HM; Sam CK Asian Pac J Allergy Immunol; 2005 Mar; 23(1):65-7. PubMed ID: 15997877 [TBL] [Abstract][Full Text] [Related]
33. An immunofluorescence technique with counterstain on fixed cells for the detection of antibodies to human herpesviruses; antibody patterns in patients with Hodgkin's disease and nasopharyngeal carcinoma. Hilgers F; Hilgers J Intervirology; 1976; 7(6):309-27. PubMed ID: 67099 [TBL] [Abstract][Full Text] [Related]
34. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups. Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990 [TBL] [Abstract][Full Text] [Related]
35. Malaria antibody levels in patients with nasopharyngeal carcinoma. Yadav M; Prasad U Southeast Asian J Trop Med Public Health; 1984 Jun; 15(2):234-7. PubMed ID: 6095462 [TBL] [Abstract][Full Text] [Related]
36. Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein-Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study. Du JL; Chen SH; Huang QH; Xie SH; Ye YF; Gao R; Guo J; Yang MJ; Liu Q; Hong MH; Cao SM Chin J Cancer; 2016 Aug; 35(1):78. PubMed ID: 27527073 [TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus-related antibody. Changes in titers after therapy for nasopharyngeal carcinoma. Neel HB; Taylor WF Arch Otolaryngol Head Neck Surg; 1990 Nov; 116(11):1287-90. PubMed ID: 2173618 [TBL] [Abstract][Full Text] [Related]
38. Serological and immunohistological assessment of Epstein-Barr virus infection in Sicilian patients with suspected nasopharyngeal carcinoma. Ammatuna P; de Thè G; Speciale R; Sammartano F; Arista S; Zerillo G Microbiologica; 1988 Apr; 11(2):89-94. PubMed ID: 2841559 [TBL] [Abstract][Full Text] [Related]
39. Detection of Epstein-Barr virus IgA/EA antibody for diagnosis of nasopharyngeal carcinoma by immunoautoradiography. Zeng J; Gong CH; Jan MG; Fun Z; Zhang LG; Li HY Int J Cancer; 1983 May; 31(5):599-601. PubMed ID: 6303967 [TBL] [Abstract][Full Text] [Related]
40. The genetic and antigenic basis for the IgA antibody response to Epstein-Barr viral capsid antigen. Ng MH; Ho HC; Kwan HC IARC Sci Publ (1971); 1978; (20):449-58. PubMed ID: 215527 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]